SDZNYSandoz Group AG

About Sandoz Group AG (SDZNY)

Sandoz Group AG (SDZNY) is a Drug Manufacturers - Specialty & Generic company headquartered in Rotkreuz, Switzerland whose shares trade over-the-counter on the OTCQX tier.

Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 800 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,500 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world's first oral penicillin in 1951, and the world's first biosimilar in 2006. In 2023, Sandoz recorded sales of USD 9.6 billion.

Products and services

Sandoz serves a clear purpose: to pioneer access for patients. We are a European champion and a global leader in Generics and Biosimilars. The off-patent medicines market in which we operate provides approximately 80% of global medicines at approximately 25% of total medication costs. We serve approximately 500 million patients per year through our global network and our medicines have an estimated annual social impact of more than USD 180 billion. In our Generics business, we develop, manufacture and market small-molecule pharmaceuticals, and manufacture and supply active pharmaceutical ingredients and intermediates to third parties globally. This business recorded net sales of USD 7.4 billion during the year ended December 31, 2023. Our Biosimilars business is a global leader with a total of eight approved and marketed products, and an extensive pipeline of 24 biologic products. Sandoz' Biosimilars have been used in clinical practice for over 15 years and are available in more than 90 countries worldwide. The business recorded net sales of USD 2.2 billion during the year ended December 31, 2023.

SDZNY key facts

Ticker symbol

SDZNY

Market tier

OTCQX

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Headquarters

Rotkreuz, Switzerland

Country of incorporation

CH

Year of incorporation

2022

Employees

20,000

Estimated market cap

$16.41B (as of Apr 9, 2025)

Shares outstanding

440,000,000

Reporting standard

International Reporting: SIX Swiss Exchange

Audit status

Audited

Fiscal year end

12/31

Latest filing

Annual Report (Dec 31, 2024)

Sandoz Group AG leadership

• Richard Saynor — CEO
• Francisco Ballester — President
• Keren Haruvi — President
• Christophe Delenta — President
• Tripti Jha — Officer
• Remco Steenbergen — CFO
• Glenn A. Gerecke — CMO
• Claire D'Abreu-Hayling — Chief Scientific Officer

Explore more: Drug Manufacturers - Specialty & Generic stocks · Healthcare sector · OTCQX stocks · OTC stocks starting with S